

LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 06171/105005	SERIAL NO. 09/371,747	FILING DATE August 10, 1999
APPLICANT Gosselin et al.		GROUP Art Unit -1614 -- 1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
<i>Me</i>	AL-2 WO 99/45935 ✓	09/16/99	World(PCT)	Lipitek International, Inc.	
<i>Me</i>	AM2- WO 96/13512 A2/A3 ✓	05/09/96	WORLD(PCT)	Genencor INT; Lipiteck INC.	
<i>Me</i>	AN2 WO 92/08727 ✓	05/29/92	World(PCT)	Consiglio Nazionale Ricerche	
<i>Me</i>	AO2 EP 0 352 248 ✓	01/24/90	Europe (EPO)	Medivir AB	
<i>Me</i>	AP 2 CA 2,206,878 ✓	03/27/97	Canada	Lipitek International Inc.	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Me</i>	CA 2 ✓	(Erroneous citation - see PTO-892 for correct cite. Robins, Morris J., "Selective Deoxygenation and Modification at C2' of Nucleosides", Nucleic Acids Chem., 98(13), (1983-03-28), XP002134809,
<i>Me</i>	CB 2 ✓	Zhu, Yong-Lian et al, "Anti -Hepatitis B Virus Activity and Metabolism of 2',3'-Dideoxy-2',3'-Didehydro-beta.-L(-)-5-Fluorocytidine", Antimicrob. Agents Chemother. (1998) 42(7), 1805-1810, XP 002134808 (7/98)
<i>Me</i>	CC 2 ✓	Lin T-S et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents, Tetrahedron 51(4), 1055, 1068, (1995-01-23)


EXAMINER L. E. Crane	DATE CONSIDERED 12/21/00
--------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Month of publication data is unavailable for this reference.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/371,747
				Filing Date	August 10, 1999
				First Named Inventor	Gosselin et al.
				Group Art Unit	-1644- 1623
Examiner Name					
Sheet	1	of	4	Attorney Docket Number	NOV 1000 06171.105005



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
see	AA	5,149,794		Yatvin et al	09-22-1992	
see	AB	5,194,654		Hostetler et al.	03-16-1993	
see	AC	5,223,263		Hostetler et al.	06-29-1993	
see	AD	5,256,641		Yatvin et al	10-01-2693 10-26-93	
see	AE	5,411,947		Hostetler et al.	05-02-1995	
see	AF	5,463,092		Hostetler et al.	10-31-1995	
see	AG	5,539,116		Liotta	07-23-1996	
see	AH	5,543,389		Yatvin et al	08-06-1996	
see	AI	5,543,390		Yatvin et al	08-06-1996	
see	AJ	5,543,391		Yatvin et al	08-06-1996	
see	AK	5,554,728		Basava et al.	09-10-1996	
see	AL	5,565,438		Chu	10-15-1996	
see	AM	5,567,688		Chu	10-22-1996	
see	AN	5,587,362		Chu	12-24-1996	
**	AO	09/330,133		Schinezi et al.		
see	AP	5,190,926		Chu	03-02-1993	
see	AQ	4,916,122		Chu	04-10-1990	

** Allowed file unavailable at this time.

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
see	AR	WO	89/02733		University of California	04-06-1989		✓
see	AS	WO	90/00555	✓	Vical, Inc.	01-25-1990		
see	AT	WO	91/16920	✓	Vical, Inc.	11-14-1991		
see	AU	WO	91/18914	✓	Vical, Inc.	12-12-1991		
see	AV	WO	91/19721	✓	Glazier	12-26-1991		
see	AW	WO	92/15308	✓	Wellcome	09-17-1992		
see	AX	WO	92/18517	✓	Yale et al.	10-29-1992		
Examiner Signature	L. E. Crane <i>[Signature]</i>					Date Considered	12/21/00	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

+

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/371,747
--------------------	------------

Filing Date	August 10, 1999
--------------------	-----------------

First Named Inventor	Gosselin et al.
----------------------	-----------------

Group Art Unit	-1614	1623
----------------	-------	------

Examiner Name

Attorney Docket Number	NOV 1000
------------------------	----------

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "MAY 18 2000" is in the center, and "PATENT & TRADEMARK" is at the bottom. The stamp is partially obscured by a vertical line on the right side.

Sheet	2	of	4
-------	---	----	---

[illegible]


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington DC 20231.

COPY FOR ☒ File ☐ Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/371,747
				Filing Date	August 10, 1999
				First Named Inventor	Gosselin et al.
				Group Art Unit	1614 - 1623
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	NOV 1000 06171.105005



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T		
Me	CA	Chang, et al., Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2',3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication, Journal of Biological Chemistry, Volume 267(20), 13938-13942 (1992). (July, 1992).			
Me	CB	Davison, et al., Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides, J. Org. Chem., 52(9), 1794-1801 (1987)			
Me	CC	Du J et al, Synthesis, "Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides," J of Med. Chem., (40)19, 2991-2993 (1997). (September 12, 1997).			
Me	CD	Furman, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" Antimicrobial Agents and Chemotherapy, 36(12) 2686-2692 (1992). (December, 1992).			
Me	CE	Hoard, et al., Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates, J. Am. Chem. Soc., 87(8), 1785-1788 (1965). (April-June, 1965).			
Me	CF	Antonin Holy "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," Collect. Czech. Chem. Commun. (1972), 37(12), 4072-87. (December, 1972).			
Me	CG	Hostetler, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch. 1992. Antimicrob Agents Chemother. 36:2025-2029 (September, 1992).			
Me	CH	Hostetler, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman. 1990. J. Biol Chem. 265:6112-7. (April 15, 1990).			
Me	CI	VERRI, Biochem. J. (1997), 328(1), 317-20. (November 15, 1997).			
Me	CJ	Gosselin, G.; Bergogne, M.-C.; Imbach, J.-L., "Synthesis and Antiviral Evaluation of -L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases", Journal of Heterocyclic Chemistry, 1993, 30 (Oct.-Nov.), 1229-1233			
Me	CK	Bloch, et al. (J. Med. Chem. (1967), 10(5), 908-12). (September, 1967).			
Me	CL	Kucera, L.S., N. Lyer, E. Leake, A. Raben, Modest E.J., D. L.W., and C. Piantadosi. 1990. AIDS Res Hum Retroviruses. 6:491-501; (Issue No. 4; Q April, 1990).			
! Month of publication data is unavailable for this reference.					
Examiner Signature	L. E. Crane			Date Considered	12/21/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

Copy For ☒ File ☐ Applicant


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/371,747
		Filing Date	August 10, 1999
		First Named Inventor	Gosselin et al.
		Group Art Unit	1614- 1623
		Examiner Name	
Sheet 4 of 4	Attorney Docket Number	NOV 1000 06171.105005	

(use as many sheets as necessary)

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
Me	DA	R. Jones and N. Bischofberger, Mini Review: Nucleotide prodrugs, Antiviral Research, 27, 1-17 (1995).	
Me	DB	Imai et al., J. Org. Chem., 34(6), 1547-1550 (June 1969).	
Me	DC	Nakayama, C., and Saneyoshi, M., Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1- - Xylofuranosyl-5-Alkyluracils and Related Nucleosides. Nucleosides, Nucleotides, 1, 139-146 (1982)	
Me	DD	MAGA et al., Biochem. J. (1993), 294(2), 381-5. (September 1, 1993).	
Me	DE	Robins, M.J., et al., Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides. J. Am. Chem. Soc. 105, 4059-4065 (1983).	
Me	DF	Korba and Milman, A cell culture assay for compounds which inhibit hepatitis B virus replication, Antiviral Res., 15:217 1991. (Issue No. 1, January, 1991).	
Me	DG	SPADARI, J. Med. Chem. (1992), 35(22), 4214-20.	
Me	DH	Morris S. Zedeck et al. Pseudomonas testosteroni, Mol. Phys. (1967), 3(4), 386-95.	
Me	DI	Robins, M. J.; Khwaja, T. A.; Robins, R. K. J. Org. Chem. 1970, 35, 636-639] (Issue No. 3; March, 1970).	
Me	DJ	Saneyoshi, M., and Satoh, E., Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines. Chem; Pharm. Bull., 27, 2518-2521 (1979);	
Me	DK	Tyrsted et al. (Biochim. Biophys. Acta (1968), 155(2), 619-22)	
Me	DL	Verri et al. Mol. Pharmacol. (1997), 51(1), 132-138 (January, 1997)	
Me	DM	Zhang, W., and Robins, M. J., Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol. Tetrahedron Lett., 33, 1177-1180 (1992). (February 25, 1992).	
Me	DN	Norbeck, Tetrahedron Letters 30 (46), 6246 (1989)	

Examiner Signature	L. E. Crane 	Date Considered	12/21/00
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington DC 20231.

COPY FOR ☒ File ☐ Applicant